Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742 | 0.97 | LIMK1 (0.66) | LIMK1ALDH1A1MKNK1TSHRKDM4E | |
| SCHEMBL16751404 | 0.79 | LIMK1 (1.00) | LIMK1ALDH1A1TSHRKDM4EGAA | |
| SCHEMBL12407778 | 0.79 | LIMK1 (0.66) | LIMK1ALDH1A1MKNK1TSHRKDM4E | |
| SCHEMBL923855 | 0.79 | LIMK1 (0.66) | LIMK1ALDH1A1MKNK1TSHRKDM4E | |
| SCHEMBL15140475 | 0.79 | LIMK1 (0.42) | LIMK1ALDH1A1MKNK1TSHRKDM4E | |
| SCHEMBL16281231 | 0.78 | LIMK1 (0.67) | LIMK1ALDH1A1MKNK1TSHRKDM4E | |
| SCHEMBL1015876 | 0.78 | SIGMAR1 (0.50) | DRD2KDR | |
| SCHEMBL6315989 | 0.78 | LIMK1 (0.69) | LIMK1ALDH1A1MKNK1TSHRKDM4E | |
| Hydrochloric Acid SCHEMBL17296432 | 0.76 | SIGMAR1 (0.49) | DRD2KDR | |
| SCHEMBL14459722 | 0.76 | LIMK1 (0.70) | LIMK1ALDH1A1TSHRKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263843-A | Dopamine D 2 Receptor-like dual ligand compounds and uses thereof | 常州大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-113979915-B | Dopamine D 2 Receptor dual ligand compounds and uses | 常州大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113979915-A | Dopamine D2Receptor dibit ligand type compound and application | 常州大学 | 2022-01-28 | — | — | CN | disclosed |
| EP-3233866-B1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-9981981-B2 | Tricyclic proteasome activity enhancing compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981981-B2 | Tricyclic proteasome activity enhancing compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2595993-B1 | TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS | HARVARD COLLEGE (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3239154-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| EP-1797099-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | Epix Delaware, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7030240-B2 | 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2006034511-A1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1622914-A2 | NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2004-12-09 | — | — | US | disclosed |
| WO-2004089312-A2 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6423716-B1 | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-07-23 | — | — | US | disclosed |
| EP-1067123-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR5A, HTR3A, HTR1A | LIMK1 2778/4885ALDH1A1 1234/4885MKNK1 3378/4885 |
| US-20040248904-A1 | New piperidinylamino-thieno[2,3-d] pyrimidine compounds | HTR5A, HTR2C, HTR1A | LIMK1 4297/4885ALDH1A1 1336/4885MKNK1 2886/4885 |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR2B, HTR3B, HTR1B | LIMK1 3892/4885ALDH1A1 1583/4885MKNK1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.